Abstract
Gastric cancer (GC) has remained one of the leading causes of cancer-related deaths globally. The development of noninvasive biomarkers in cancer diagnosis and treatment has gained substantial traction in recent years. Recent evidence highlights hypercoagulation as a promising prognostic biomarker, particularly in locally advanced GC (LAGC) who underwent radical resection after neoadjuvant immunochemotherapy (NICT). A recent study by Li et al showed that hypercoagulation is a valuable prognostic indicator for patients with LAGC who have undergone radical resection following NICT. While the study addresses an important clinical issue and provides insightful findings, the present study offered valuable insights; the applicability of these findings was constrained by the retrospective design, the focus on a single center, and the small sample size of the existing studies. Additionally, vital confounders, such as preoperative comorbidities and systemic inflammation, are inadequately addressed. Future studies should focus on prospective multicenter trials, incorporating advanced predictive models such as machine learning algorithms to integrate coagulation markers with other clinical variables for personalized risk stratification. In addition, we are required to validate findings to examine the biological mechanisms correlating hypercoagulation to tumor progression. Integrating machine learning, comprehensive biomarker panels, and real-world data would allow the researchers to have personalized risk stratification, improve predictive accuracy, and optimize clinical decision-making. Finally, A multidisciplinary approach, including lifestyle interventions and imaging modalities, is essential to improve outcomes among patients with GC.